Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TDゼット液/ゼリー (TD Zette Liquid/Jelly) is a local hemostatic combination drug developed by Bee Brand Medico Dental and manufactured by Toyo Pharmaceutical. It is approved in Japan for the control of minor bleeding in the oral cavity during dental procedures, such as crown preparation, cavity preparation, gingival retraction, and gingival shaping. The drug is formulated as a liquid or a jelly and contains three active ingredients: aluminum chloride (25%), which acts as an astringent to coagulate tissue proteins and constrict local blood vessels to stop bleeding; cetylpyridinium chloride (0.5%), an antiseptic that prevents infection; and lidocaine (5.25%), a local anesthetic that suppresses pain at the application site.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aluminum chloride + cetylpyridinium chloride + lidocaine.